Form 4: Neurocrine Biosciences CFO Matt Abernethy Reports Stock Transactions

Chief Financial Officer of Neurocrine Biosciences, Matt Abernethy, reports the acquisition and disposition of common stock and restricted stock units.

Summary

• Matt Abernethy, the CFO of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On February 8, 2025, Abernethy acquired 1,860 shares of common stock through the vesting of restricted stock units (RSUs).
• Also on February 8, 2025, 1,860 Restricted Stock Units vested.
• On February 10, 2025, Abernethy disposed of 980 shares of common stock at an average price of $118.274 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2021.
• Following these transactions, Abernethy beneficially owns 33,561 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an insider under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into insider trading activity, but the pre-planned nature of the sales mitigates any significant concerns.

Key Dates

Keywords

Form 4, Neurocrine Biosciences, Matt Abernethy, Stock Sale, RSU, Beneficial Ownership, NBIX, CFO, 10b5-1 Trading Plan